Background: There is worldwide growing awareness of alpha-1-antitrypsin deficiency (AATD), a major hereditary disorder in Caucasians. The gold standard for its laboratory diagnosis is thin-layer isoelectric focusing, which should be performed in reference laboratories. Objectives: The aim of this study was to check the characteristics of a commercially available amplification-reverse hybridization assay kit in detecting at a molecular level the alpha-1-antitrypsin (AAT) Z and S variants, i.e. the most frequent variants associated with AATD, by comparing its performance with DNA restriction fragment length polymorphism. Methods: We studied samples from 36 subjects enrolled in the Italian National Registry for Severe Alpha-1-antitrypsin Deficiency. Based on previous plasma isoelectric focusing typing, we selected samples with the following phenotypes: MM (9 samples), MS (9 samples), SZ (3 samples), MZ (11 samples), ZZ (3 samples), and a rare variant (1 sample). DNA was extracted by the standard method. The presence of the AAT Z and S gene variants was determined by the amplification-reverse hybridization test kit, following the manufacturer’s instructions, and by the restriction fragment length polymorphism technique, according to established procedures. Results: We found that the identification of the AAT Z and S gene variants obtained by the amplification-reverse hybridization test kit was completely in agreement with that obtained by the restriction fragment length polymorphism technique. Conclusions: We conclude that the test kit provides a fast, easy and unambiguous identification of Z and S alleles. Because of its transferability to routine laboratories, the test kit may be useful in identifying cases of severe AATD, thus resulting in increasing awareness of this rare disorder.

Keywords:
Alpha-1-antitrypsin, DNA, Isoelectric focusing, Polymerase chain reaction, Restriction fragment length polymorphism
1.
Barker A, Brantly M, Campbell E, et al: Alpha-1-antitrypsin deficiency: Memorandum from WHO meeting. Bull WHO 1997;75:397–415.
2.
McElvaney NG, Stoller JK, Buist AS, et al: Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of α1-antitrypsin deficiency. Chest 1997;111:394–403.
3.
Brantly M: Laboratory diagnosis of α1AT deficiency; in Crystal RG (ed): Alpha 1-Antitrypsin Deficiency. New York, Dekker, 1996, pp 211–226.
4.
Brantly ML, Paul LD, Miller BH, et al: Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138:327–336.
5.
Luisetti M, Massi G, Massobrio M, et al: A national program for detection of α1-antitrypsin deficiency in Italy. Respir Med 1999;93:169–172.
6.
Turino GM, Barker AF, Brantly ML, et al: Clinical features of individuals with PI*SZ phenotype of α1-antitrypsin deficiency. Am J Respir Crit Care Med 1996;154:1718–1725.
7.
Rieger S, Riemer H, Mannhalter C: Multiplex PCR assay for the detection of genetic variants of α1-antitrypsin. Clin Chem 1999;45:688–690.
8.
Massi G, Marano G, Catalano F, et al: Silver-stained phenotyping alpha-1-antitrypsin in dried blood and serum specimens. Clin Chem 1984;30:1674–1676.
9.
Massi G, Fabiano A, Ragusa D, et al: Characterization of alpha-1-antitrypsin by isoelectrofocusing on ultrathin polyacrylamide gel layer. Hum Genet 1979;53:91–95.
10.
Klasen EC, Hofker MH, van Paassen, et al: Detection of alpha-1-antitrypsin deficiency variants by synthetic oligonucleotide hybridization. Clin Chim Acta 1987;170:201–207.
11.
Benetazzo MG, Gilé LS, Bombieri C, et al: α1-antitrypsin TAQ I polymorphism and α1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir Med 1999;93:648–654.
12.
GenoType® Alpha-1-Antitrypsin Instruction Booklet, p 4.
13.
Takahashi H, Nukiwa T, Satoh K, et al: Characterization of the gene and protein of the alpha-1-antitrypsin deficiency allele Mprocida. J Biol Chem 1988;263:15528–15534.
14.
The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Respir Crit Care Med 1998;158:49–59.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.